|
| Lanfear Capital's current portfolio
of investments demonstrates our commitment to partner with entrepreneurs
to create value. We are proud of our portfolio companies and
we are pleased with the working relationships that we have developed
with Board members and management teams. |
|
| InteKrin Therapeutics, Inc. |
|
| |
InteKrin Therapeutics is a clinical-stage, privately held BioPharma company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. Diseases such as diabetes, metabolic syndrome, and cancer are increasingly in need of novel treatments that provide patients with better treatment alternatives and help to curb soaring healthcare costs. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity. |
 |
| |
|
|
|
| |
|
| Saronyx, Inc. |
|
| |
Saronyx Inc., provides decision support and workflow
integration tools for drug development program management. A
bottom-up approach embracing best practices is integrated with
powerful top-down visualization views to provide transparency
and feedback in a true Six-Sigma fashion. Dynamic navigation
provides rapid drill down and analysis into specific information
captured at each organizational level and every process stage.
|
 |
| |
|
|
|
| |
|
| Anthera Pharmaceuticals, Inc. |
|
| |
Anthera Pharmaceuticals is a start-up pharmaceutical
company focused on the in-licensing of promising clinical candidates
for the treatment of serious respiratory and inflammatory diseases.
Anthera has identified four clinical stage products which have
the potential to address a variety of these target diseases
including: Acute Lung Injury, Cystic Fibrosis, COPD, Asthma,
and idiopathic pulmonary fibrosis. |
 |
| |
|
|
|
| |
|
| Coapt Systems, Inc. |
|
| |
Coap Systems Inc. develops bio-absorbable implants
for use in soft tissue fixation during facial cosmetic surgery
procedures. Featuring MultiPoint™ technology, their products
enable physician to reliably place and shape soft tissue without
sutures, pins, or screws. |
 |
| |
|
|
|
| |
| BAS Medical |
| |
BAS Medical is a private, development-stage company founded
in 2003 with a mission to develop and market a novel technology
to accelerate and improve orthodontic treatments. The company
has acquired worldwide rights to recombinant relaxin, a naturally
occurring hormone with several distinct biological activities,
including vasodilation, angiogenesis and inhibition of fibrosis.
LanfearCapital is a Strategic Advisor to the company. |
 |
| |
|
|
|
| |
|
|
| |
EndoVx |
|
| |
EndoVx's approach has showed effective long term weight loss
in a prior human surgical study. Their proprietary procedure
is quick, bloodless, and done on an out-patient basis. EndoVx
is moving forward to demonstrate the performance of the system
and generate additional clinical data. Lanfear Capital is a
Board Observer of the company. |
EndoVx |
| |
|
|
|
| |
|
|
| Asilomar Pharmaceuticals |
| |
Asilomar Pharmaceuticals has staked an early claim to receptor-mediated
drug delivery to the peripheral nervous system (PNS). This company
is combining its proprietary "linker" chemistry technology
with off-patent (generic) pharma-ceuticals to treat PNS-related
disorders, like shingles, neuropathic pain, diabetic neuropathy,
and herpes. There are only marginally effective treatments or
none at all for these very large markets. Asilomar has patented
a "linker" chemistry which when conjugated with a
generic drug, the resulting conjugate is transported from the
end of a nerve up along its length, avoiding the blood-brain
barrier, and bringing the active drug to the neuronal cells
along the neural pathway. LanfearCapital invested alongside
Sears Capital, Asset Management, SBV Ventures and several angel
investors in the first round. LanfearCapital is a Strategic
Advisor to the company. |
Asilomar |
| |
|
|
|
 |
| |
|
|
